{"gene":"TIGIT","run_date":"2026-04-28T21:42:59","timeline":{"discoveries":[{"year":2011,"finding":"TIGIT has T cell-intrinsic inhibitory functions independent of APCs; agonistic anti-TIGIT antibody directly attenuates TCR-driven activation signals in T cells, and TIGIT-deficient mice show hyperproliferative T cell responses and increased susceptibility to autoimmunity.","method":"Agonistic anti-TIGIT antibody stimulation, microarray analysis of stimulated T cells, TIGIT knockout mouse model","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — clean KO phenotype plus agonistic antibody functional dissection, replicated across multiple experimental approaches in one study","pmids":["21199897"],"is_preprint":false},{"year":2011,"finding":"TIGIT (VSTM3) binds to nectin-family ligands CD155 (PVR) and CD112, which are also ligands for the activating receptor CD226, establishing a regulatory network analogous to CD28/CTLA-4; soluble VSTM3 attenuates T cell responses in vitro and in vivo, and VSTM3-deficient animals are more sensitive to autoimmune challenges.","method":"Ligand binding assays, soluble fusion protein treatment in vitro and in vivo, gene-deficient mouse autoimmune models","journal":"European journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (binding, functional, KO), confirmed in vivo","pmids":["21416464"],"is_preprint":false},{"year":2014,"finding":"TIGIT functions as a co-inhibitory receptor that limits CD8+ T cell effector function in tumors and chronic viral infection; CD226 dimerization is disrupted by direct TIGIT–CD226 interaction in cis, and antibody co-blockade of TIGIT and PD-L1 synergistically enhances CD8+ T cell responses.","method":"Antibody blockade in murine tumor and viral infection models, assessment of CD226 dimerization upon TIGIT interaction","journal":"Cancer cell","confidence":"High","confidence_rationale":"Tier 2 — multiple in vivo models plus direct molecular interaction data, strong epistasis evidence","pmids":["25465800"],"is_preprint":false},{"year":2015,"finding":"The Fap2 protein of Fusobacterium nucleatum directly interacts with human TIGIT on NK cells and T cells, inhibiting NK cell cytotoxicity and T cell activity, thereby enabling tumor immune evasion.","method":"F. nucleatum mutant library screen, direct protein interaction assays, NK cell cytotoxicity assays","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 — mutant library screen identifying specific bacterial protein, functional cytotoxicity assays, replicated across multiple tumor types","pmids":["25680274"],"is_preprint":false},{"year":2016,"finding":"TIGIT enhances Th2 recall responses and allergic disease; its interaction with CD155 on dendritic cells promotes Th2 polarization, and in vivo TIGIT blockade suppresses hallmarks of allergic airway disease including lung eosinophilia and IgE production.","method":"In vitro Th2 polarization cultures, in vivo allergic airway disease model with TIGIT blockade","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 — multiple in vitro and in vivo readouts, single lab","pmids":["27016609"],"is_preprint":false},{"year":2017,"finding":"TIGIT-CD155 interaction promotes NK cell functional maturation (education) in a MHC-I-independent manner; TIGIT+ NK cells from CD155-deficient hosts show functional impairment, and TIGIT deficiency impairs missing-self recognition independently of CD226.","method":"TIGIT-KO and CD155-KO mouse models, NK cell functional assays, missing-self rejection assays","journal":"Journal of autoimmunity","confidence":"High","confidence_rationale":"Tier 2 — KO of both receptor and ligand with specific phenotypic readouts, mechanistically dissected from CD226","pmids":["28438433"],"is_preprint":false},{"year":2017,"finding":"CD155/TIGIT signaling inhibits CD8+ T cell metabolism and effector function in gastric cancer; CD155 on gastric cancer cells binds TIGIT and deprives T cells of glucose, impairing IFNγ production, an effect reversed by TIGIT blockade or additional glucose.","method":"T cell-tumor coculture assays, CD155 silencing/overexpression, glucose supplementation rescue, in vivo tumor model","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 — multiple genetic and pharmacologic interventions with consistent metabolic and functional phenotype readouts","pmids":["28883004"],"is_preprint":false},{"year":2018,"finding":"TIGIT is highly expressed on NK cells in tumor-bearing mice and cancer patients; TIGIT blockade prevents NK cell exhaustion and promotes NK cell-dependent tumor immunity and CD8+ T cell tumor-specific immunity.","method":"TIGIT antibody blockade in multiple mouse tumor models, NK cell depletion experiments, flow cytometry","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 2 — multiple tumor models, NK depletion epistasis, replicated findings","pmids":["29915296"],"is_preprint":false},{"year":2018,"finding":"TIGIT on CD4+ Tregs in melanoma augments Treg suppressive function and stability; high TIGIT expression with low CD226 on Tregs enhances their suppressive capacity, while CD226 expression disrupts Treg suppression.","method":"Flow cytometry of patient tumor samples, functional Treg suppression assays, TIGIT/CD226 expression analysis","journal":"JCI insight","confidence":"Medium","confidence_rationale":"Tier 3 — functional correlation data with patient samples, single lab","pmids":["30046006"],"is_preprint":false},{"year":2019,"finding":"Glucocorticoid receptor (GR) signaling directly upregulates TIGIT expression on T cells and iNKT cells; stress-induced TIGIT upregulation is reversed by the GR antagonist RU486, and Lck-Cre GR knockout mice fail to upregulate TIGIT under stress.","method":"GR antagonist treatment, chemical sympathectomy, Cre/Lox GR conditional knockout, corticosterone administration in vitro and in vivo","journal":"Brain, behavior, and immunity","confidence":"High","confidence_rationale":"Tier 2 — conditional KO plus pharmacological intervention, multiple cell types and models","pmids":["31108170"],"is_preprint":false},{"year":2020,"finding":"Membrane-bound CD155 on tumor cells triggers CD226 internalization and degradation on NK cells, resulting in decreased NK cell-mediated tumor reactivity; IL-15 upregulates both TIGIT and CD226 on tumor-infiltrating NK cells and, combined with TIGIT blockade, increases NK cell cytotoxicity.","method":"CD226 internalization assays, TIGIT-specific NK cell transfer, mouse melanoma metastasis models, flow cytometry","journal":"Clinical cancer research","confidence":"High","confidence_rationale":"Tier 2 — mechanistic dissection of CD226 degradation, genetic (TIGIT-KO NK cells), and pharmacologic approaches","pmids":["32591463"],"is_preprint":false},{"year":2020,"finding":"TIGIT on memory B cells suppresses immune responses by directly inhibiting T cell proliferation and by arresting pro-inflammatory dendritic cell function via TIGIT/CD155 interactions; TIGIT+ memory B cells also express IL-10, TGF-β1, granzyme B, PD-L1, CD39/CD73, and TIM-1.","method":"TIGIT+ B cell isolation, co-culture with T cells and dendritic cells, TIGIT blockade experiments, flow cytometry","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 3 — functional co-culture assays with defined mechanistic readouts, single lab","pmids":["33750787"],"is_preprint":false},{"year":2020,"finding":"B cell-specific TIGIT deletion causes spontaneous CNS inflammation and paralysis; Tim-1 signaling-dependent TIGIT expression on B cells is essential for maintaining CNS-specific tolerance.","method":"B cell-specific TIGIT conditional knockout mice, transcriptomic analysis, in vivo neuroinflammation model","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 — clean conditional KO with specific CNS inflammatory phenotype, transcriptomic analysis","pmids":["32668241"],"is_preprint":false},{"year":2020,"finding":"Anti-TIGIT antibody therapeutic effect requires functional Fc binding to FcγRs on myeloid cells; TIGIT blockade does not deplete Tregs but instead induces 'reverse activating signals' through FcγRs causing cytokine/chemokine expression and a granzyme B/perforin response distinct from anti-PD-1.","method":"Mouse tumor models with Fc-functional vs. Fc-null anti-TIGIT antibodies, myeloid cell analysis, cytokine profiling","journal":"Frontiers in immunology","confidence":"Medium","confidence_rationale":"Tier 2 — mechanistic dissection of Fc requirement in vivo, single lab","pmids":["33117369"],"is_preprint":false},{"year":2022,"finding":"TIGIT blockade in AML repolarizes TIGIT+ M2 leukemia-associated macrophages to M1 phenotype, increases secretion of M1-associated cytokines, and augments anti-CD47-mediated phagocytosis of AML cells.","method":"In vitro TIGIT blockade on primary LAMs, flow cytometry, cytokine measurement, phagocytosis assays","journal":"Journal for immunotherapy of cancer","confidence":"Medium","confidence_rationale":"Tier 3 — functional in vitro assays with primary patient-derived macrophages, single lab","pmids":["36549780"],"is_preprint":false},{"year":2022,"finding":"TIGIT, upon binding to CD155, is phosphorylated and recruits SHIP-1, which inhibits NF-κB and ERK activation in CD8+ T cells, resulting in reduced cytokine production; TIGIT blockade attenuates SHIP-1 inhibitory effects and restores NF-κB and ERK signaling.","method":"Western blotting for NF-κB and ERK pathway after TIGIT/CD155 blockade, phosphorylation assays, in vivo tumor model","journal":"Journal of translational medicine","confidence":"Medium","confidence_rationale":"Tier 2 — defined intracellular signaling pathway with western blot evidence, in vivo confirmation","pmids":["35729552"],"is_preprint":false},{"year":2022,"finding":"Impaired TIGIT expression on MS-derived B cells is mediated by dysregulation of transcription factor TCF4; TIGIT on B cells suppresses proliferation of IL-17-producing circulating follicular helper T cells via the TIGIT/CD155 axis.","method":"Comparative gene expression analysis, co-culture assays of B cells and cTfh cells, TCF4 dysregulation analysis","journal":"The Journal of clinical investigation","confidence":"Medium","confidence_rationale":"Tier 2 — TCF4-mediated transcriptional mechanism identified, functional TIGIT/CD155 suppression demonstrated","pmids":["36250467"],"is_preprint":false},{"year":2023,"finding":"TIGIT ligation with CD155 causes TIGIT to reorganize into dense nanoclusters at the immune synapse that coalesce with TCR-rich clusters; this reduces cytokine secretion in a manner dependent on TIGIT's intracellular ITT-like signalling motif, independent of CD226 co-expression.","method":"Super-resolution microscopy, immune synapse imaging, ITT-motif mutagenesis, cytokine secretion assays on matched tumor/blood samples","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 — super-resolution structural imaging combined with mutagenesis of signaling motif and functional readout, mechanistically rigorous","pmids":["37596248"],"is_preprint":false},{"year":2023,"finding":"TIGIT mediates activation-induced cell death (AICD) of ILC2s during chronic airway allergy; ILC2 interaction with CD155 on macrophages promotes apoptosis of TIGIT+ ILC2s, and genetic ablation of Tigit or TIGIT blockade promotes ILC2 survival and worsens chronic allergic inflammation.","method":"TIGIT lineage tracer mice, ILC2 apoptosis assays, Tigit knockout mice, anti-TIGIT antagonistic antibody treatment, chromatin accessibility analysis","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 1–2 — lineage tracing, KO, and pharmacologic blockade with mechanistic chromatin analysis","pmids":["37036426"],"is_preprint":false},{"year":2023,"finding":"TIGIT interacts with nectin-4 as a novel ligand through the membrane-distal ectodomain of nectin-4; this interaction is weaker than TIGIT:nectin-2 binding and inhibits NK cell cytotoxicity; structure-guided mutagenesis mapped the nectin-4 binding interface on TIGIT.","method":"Surface plasmon resonance, structure-guided mutagenesis, NK cell cytotoxicity assays","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 1 — biophysical binding assay with mutagenesis, single lab","pmids":["37542773"],"is_preprint":false},{"year":2022,"finding":"Crystal structure of anti-TIGIT antibody MG1131 bound to TIGIT shows that MG1131 blocks the PVR-TIGIT interaction interface; functional assays confirm MG1131 increases NK cell-mediated tumor killing, inhibits Treg suppression, and restores IFNγ secretion from myeloma patient PBMCs.","method":"X-ray crystallography, competitive binding assays, NK cytotoxicity assays, Treg suppression assays","journal":"mAbs","confidence":"High","confidence_rationale":"Tier 1 — crystal structure with functional validation across multiple cell types","pmids":["35090381"],"is_preprint":false},{"year":2023,"finding":"Anti-TIGIT agonistic antibody suppresses activation of follicular helper T (Tfh) and peripheral helper T (Tph) cells that highly express TIGIT, and enhances suppressive function of naïve regulatory T cells, in human TIGIT knock-in mice.","method":"Anti-hu-TIGIT agonistic mAb generation, hu-TIGIT knock-in mouse model, CD4+ T cell functional assays","journal":"Communications biology","confidence":"Medium","confidence_rationale":"Tier 2 — humanized knock-in model with agonistic antibody, functional cell assays, single lab","pmids":["37161050"],"is_preprint":false},{"year":2023,"finding":"Anti-TIGIT activity against myeloma depends on FcγR binding; anti-TIGIT antibodies engaging FcγRs synergize with lenalidomide in a CD8+ T cell-dependent manner post-transplantation, suppressing T cell exhaustion and enhancing effector function specifically in the bone marrow tumor microenvironment.","method":"Fc-functional vs. Fc-null anti-TIGIT comparison, CRBN mouse model, CD8+ T cell depletion, bone marrow CD8 T cell phenotyping","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 — FcγR requirement mechanistically established with isotype controls plus CD8 depletion epistasis, in vivo","pmids":["36512425"],"is_preprint":false},{"year":2024,"finding":"CD155/TIGIT signaling disrupts glucose metabolism of CD8+ T cells in TNBC by suppressing PI3K/AKT/mTOR signaling pathway activation, reducing glycolytic-related proteins and cytokine production; TIGIT blockade restores PI3K/AKT/mTOR activation and cytokine production.","method":"Western blotting for PI3K/AKT/mTOR pathway, glucose/lactate assays, in vitro and in vivo TIGIT blockade","journal":"Cell communication and signaling","confidence":"Medium","confidence_rationale":"Tier 2 — defined intracellular pathway with metabolic readouts, in vivo confirmation, single lab","pmids":["38216949"],"is_preprint":false},{"year":2024,"finding":"CD155 on CTCs is transcriptionally regulated by the FAK/JNK/c-Jun cascade in a platelet contact-dependent manner; CD155 on CTCs inhibits NK cell cytotoxicity specifically by engaging TIGIT (but not CD96 or DNAM-1), and TIGIT antibody blockade restores NK immunosurveillance and reduces tumor metastasis.","method":"Competition assays, cytotoxicity experiments, FAK/JNK/c-Jun pathway analysis, in vitro/ex vivo/in vivo NK assays","journal":"Hepatology","confidence":"Medium","confidence_rationale":"Tier 2 — receptor specificity dissected by competition assays, FAK/JNK/c-Jun cascade identified, in vivo validation","pmids":["38779918"],"is_preprint":false},{"year":2024,"finding":"TIGIT+CCR7- Tregs inhibit CD226+CCR7-CD8+ cytotoxic T cells via TGF-β signaling in type 1 diabetes; CD226 inhibition in mouse models postpones insulitis onset and reduces hyperglycemia severity.","method":"Single-cell RNA sequencing, cell communication analysis, in vitro functional assays, cyclophosphamide- and STZ-induced mouse diabetes models with CD226 inhibition","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 — scRNA-seq cell communication plus in vitro TGF-β assays and in vivo CD226 inhibition, single lab","pmids":["39406740"],"is_preprint":false}],"current_model":"TIGIT is an inhibitory immune checkpoint receptor expressed on T cells, NK cells, Tregs, and B cells that suppresses immune activation through multiple mechanisms: direct cell-intrinsic signaling via its intracellular ITT-like motif (forming TCR-proximal nanoclusters and recruiting SHIP-1 to inhibit NF-κB/ERK), competition with the activating receptor CD226 for shared ligands CD155 (PVR) and CD112 (nectin-2), CD226 internalization/degradation triggered by membrane-bound CD155, FcγR-dependent myeloid cell modulation by anti-TIGIT antibodies, promotion of Treg suppressive function, metabolic suppression of CD8+ T cells via the PI3K/AKT/mTOR and glucose utilization pathways, and induction of ILC2 activation-induced cell death through CD155 on macrophages; its expression is transcriptionally regulated by glucocorticoid receptor signaling and TCF4, and its ligand binding extends to nectin-4, while bacterial Fap2 protein exploitation of TIGIT represents an additional tumor immune evasion mechanism."},"narrative":{"teleology":[{"year":2011,"claim":"Establishing that TIGIT functions as a T cell-intrinsic co-inhibitory receptor—not merely an APC-targeting molecule—resolved the question of whether TIGIT directly suppresses T cell activation, showing that TIGIT-deficient mice develop hyperproliferative T cell responses and autoimmunity susceptibility.","evidence":"Agonistic anti-TIGIT antibody stimulation, microarray analysis, and TIGIT knockout mouse model","pmids":["21199897"],"confidence":"High","gaps":["Intracellular signaling pathway downstream of TIGIT not yet identified","Whether TIGIT inhibition operates on cell types beyond T cells unclear"]},{"year":2011,"claim":"Identifying CD155 and CD112 as shared ligands for both TIGIT and the activating receptor CD226 established the TIGIT/CD226 regulatory axis as a paradigm analogous to CTLA-4/CD28, explaining how TIGIT achieves inhibition partly through ligand competition.","evidence":"Ligand binding assays, soluble fusion protein treatment in vitro/in vivo, gene-deficient mouse autoimmune models","pmids":["21416464"],"confidence":"High","gaps":["Whether TIGIT outcompetes CD226 through affinity or stoichiometry not resolved","Additional ligands not yet explored"]},{"year":2014,"claim":"Demonstrating that TIGIT disrupts CD226 homodimerization in cis and that co-blockade of TIGIT with PD-L1 synergistically restores CD8+ T cell function revealed a dual inhibitory mechanism (ligand competition plus direct receptor-receptor interaction) and established the rationale for combination checkpoint immunotherapy.","evidence":"Antibody blockade in murine tumor and chronic viral infection models, CD226 dimerization assays","pmids":["25465800"],"confidence":"High","gaps":["Structural basis of cis TIGIT-CD226 interaction unresolved","Whether cis disruption versus ligand competition dominates in different contexts unknown"]},{"year":2015,"claim":"The discovery that Fusobacterium nucleatum Fap2 protein directly binds TIGIT to inhibit NK cell and T cell cytotoxicity revealed a microbial co-option of TIGIT for immune evasion in colorectal cancer.","evidence":"F. nucleatum mutant library screen, direct protein interaction assays, NK cell cytotoxicity assays","pmids":["25680274"],"confidence":"High","gaps":["Binding interface of Fap2 on TIGIT not structurally characterized","Whether other bacterial species exploit TIGIT unknown"]},{"year":2017,"claim":"Showing that TIGIT-CD155 interaction drives MHC-I-independent NK cell education and that tumor-derived CD155 suppresses CD8+ T cell glucose metabolism linked TIGIT's inhibitory role to both NK cell maturation and metabolic reprogramming of effector cells.","evidence":"TIGIT-KO and CD155-KO mouse models with NK functional assays; T cell-tumor coculture with CD155 silencing/overexpression and glucose supplementation rescue","pmids":["28438433","28883004"],"confidence":"High","gaps":["Which metabolic sensors downstream of TIGIT mediate glucose deprivation effects not identified","NK education mechanism molecularly undefined"]},{"year":2018,"claim":"Demonstrating that TIGIT blockade prevents NK cell exhaustion in tumors and that high TIGIT/low CD226 on tumor-infiltrating Tregs enhances suppressive function established TIGIT as a functional checkpoint on multiple immune cell lineages within the tumor microenvironment.","evidence":"TIGIT antibody blockade in multiple mouse tumor models with NK depletion epistasis; flow cytometry and Treg suppression assays on melanoma patient samples","pmids":["29915296","30046006"],"confidence":"High","gaps":["Whether TIGIT signaling in Tregs and NK cells uses identical downstream pathways unclear","Treg data correlative without genetic Treg-specific deletion"]},{"year":2019,"claim":"Identifying glucocorticoid receptor signaling as a direct transcriptional regulator of TIGIT expression on T cells linked neuroendocrine stress pathways to immune checkpoint regulation.","evidence":"GR antagonist RU486 treatment, Lck-Cre conditional GR knockout, corticosterone administration in vitro/in vivo","pmids":["31108170"],"confidence":"High","gaps":["Whether GR binds the TIGIT promoter directly or through intermediary factors not resolved","Relevance to tumor-associated stress not tested"]},{"year":2020,"claim":"Revealing that membrane-bound CD155 triggers CD226 internalization/degradation on NK cells, that anti-TIGIT therapeutic efficacy requires FcγR engagement on myeloid cells, and that B cell-specific TIGIT deletion causes spontaneous CNS inflammation collectively expanded TIGIT biology beyond direct receptor blockade to include receptor dynamics, Fc-dependent myeloid modulation, and B cell tolerance.","evidence":"CD226 internalization assays and TIGIT-KO NK transfer (PMID:32591463); Fc-functional vs. Fc-null anti-TIGIT antibodies in mouse tumor models (PMID:33117369); B cell-specific conditional TIGIT KO mice developing CNS pathology (PMID:32668241); TIGIT+ B cell co-culture with T cells and DCs (PMID:33750787)","pmids":["32591463","33117369","32668241","33750787"],"confidence":"High","gaps":["Molecular mechanism of Fc-dependent 'reverse activating signals' through FcγR incompletely characterized","Whether B cell TIGIT tolerance function is CD155-dependent not definitively shown"]},{"year":2022,"claim":"Defining the SHIP-1-dependent NF-κB/ERK inhibitory signaling cascade downstream of TIGIT phosphorylation, identifying TCF4 as a transcriptional regulator of TIGIT on B cells, solving the TIGIT–anti-TIGIT antibody crystal structure, and confirming FcγR-dependent anti-TIGIT/lenalidomide synergy in myeloma provided intracellular signaling, transcriptional, structural, and therapeutic mechanistic resolution.","evidence":"Western blot for NF-κB/ERK after TIGIT/CD155 blockade with SHIP-1 recruitment (PMID:35729552); TCF4 dysregulation analysis in MS B cells (PMID:36250467); X-ray crystallography of MG1131-TIGIT complex (PMID:35090381); Fc-functional vs. Fc-null anti-TIGIT with CD8 depletion in myeloma model (PMID:36512425)","pmids":["35729552","36250467","35090381","36512425"],"confidence":"Medium","gaps":["Whether SHIP-1 is the sole proximal effector or acts with other phosphatases unknown","TCF4 regulation based on patient-derived correlative data, direct TCF4 binding to TIGIT locus not shown"]},{"year":2023,"claim":"Super-resolution imaging revealed that TIGIT reorganizes into dense nanoclusters at the immune synapse that coalesce with TCR clusters in an ITT-like motif-dependent manner, establishing the spatial mechanism of TIGIT-mediated inhibition; simultaneously, nectin-4 was identified as an additional TIGIT ligand, and TIGIT was shown to mediate ILC2 activation-induced cell death via CD155 on macrophages.","evidence":"Super-resolution microscopy with ITT-motif mutagenesis (PMID:37596248); SPR and structure-guided mutagenesis for nectin-4 binding (PMID:37542773); TIGIT lineage tracer mice, KO, and anti-TIGIT blockade with ILC2 apoptosis assays (PMID:37036426)","pmids":["37596248","37542773","37036426"],"confidence":"High","gaps":["Whether nanocluster formation occurs with all TIGIT ligands or is CD155-specific not tested","Nectin-4 functional relevance in vivo not established","Downstream apoptotic pathway in ILC2s not molecularly defined"]},{"year":2024,"claim":"Defining PI3K/AKT/mTOR as the metabolic signaling axis suppressed by CD155/TIGIT in CD8+ T cells, and showing that platelet-contact-induced CD155 on circulating tumor cells specifically engages TIGIT (not CD96 or DNAM-1) to evade NK surveillance, refined the metabolic and metastatic evasion mechanisms of the TIGIT axis.","evidence":"Western blotting for PI3K/AKT/mTOR with glucose/lactate assays in TNBC model (PMID:38216949); receptor competition assays and FAK/JNK/c-Jun pathway analysis in hepatocellular CTC-NK model (PMID:38779918)","pmids":["38216949","38779918"],"confidence":"Medium","gaps":["Whether PI3K/AKT/mTOR suppression is downstream of SHIP-1 or represents a parallel pathway not resolved","In vivo validation of CTC-specific CD155/TIGIT metastasis axis limited to one tumor type"]},{"year":null,"claim":"Outstanding questions include: (1) how TIGIT's multiple intracellular signaling modules (ITT-like motif, SHIP-1, PI3K/AKT/mTOR suppression) are hierarchically integrated; (2) whether TIGIT nanocluster formation is ligand-specific and how it relates to cis CD226 disruption at the structural level; (3) the physiological relevance of nectin-4 as a TIGIT ligand in vivo; and (4) which Fc-effector mechanism (ADCC, reverse signaling, or both) drives therapeutic anti-TIGIT antibody efficacy in human tumors.","evidence":"Open question derived from cumulative literature gaps","pmids":[],"confidence":"Low","gaps":["Integrated signaling model connecting SHIP-1, PI3K, and nanocluster formation missing","No resolved structure of TIGIT-CD226 cis complex","Nectin-4 in vivo studies lacking","Human FcγR mechanism for anti-TIGIT not mechanistically dissected"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[0,2,15,17]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[1,5,15,17]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[2,10,17,20]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[0,2,7,8,12,15,17]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[6,15,23]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[18]}],"complexes":[],"partners":["CD155","CD112","CD226","SHIP-1","FAP2","NECTIN-4"],"other_free_text":[]},"mechanistic_narrative":"TIGIT is an inhibitory immune checkpoint receptor expressed on T cells, NK cells, regulatory T cells, ILC2s, and B cells that restrains immune activation through multiple convergent mechanisms: cell-intrinsic signaling via its ITT-like motif that recruits SHIP-1 to suppress NF-κB/ERK pathways, competitive antagonism of the co-activating receptor CD226 for shared nectin-family ligands (CD155/PVR, CD112, nectin-4), and direct disruption of CD226 homodimerization in cis [PMID:21199897, PMID:25465800, PMID:35729552, PMID:37596248]. Upon CD155 engagement, TIGIT reorganizes into TCR-proximal nanoclusters at the immune synapse to dampen cytokine secretion, suppresses CD8+ T cell glucose metabolism via inhibition of PI3K/AKT/mTOR signaling, and promotes activation-induced cell death of ILC2s, while on Tregs it enhances suppressive capacity and stability [PMID:37596248, PMID:28883004, PMID:38216949, PMID:37036426, PMID:30046006]. TIGIT also functions on B cells to maintain tolerance—B cell-specific TIGIT deletion causes spontaneous CNS inflammation—and its transcriptional regulation involves glucocorticoid receptor signaling and TCF4 [PMID:32668241, PMID:31108170, PMID:36250467]. The Fusobacterium nucleatum virulence factor Fap2 directly engages TIGIT to inhibit NK and T cell cytotoxicity, representing a microbial immune evasion strategy, while therapeutic anti-TIGIT antibodies exert effects that depend critically on Fc-FcγR engagement with myeloid cells [PMID:25680274, PMID:33117369, PMID:36512425]."},"prefetch_data":{"uniprot":{"accession":"Q495A1","full_name":"T-cell immunoreceptor with Ig and ITIM domains","aliases":["V-set and immunoglobulin domain-containing protein 9","V-set and transmembrane domain-containing protein 3"],"length_aa":244,"mass_kda":26.3,"function":"Inhibitory receptor that plays a role in the modulation of immune responses. Suppresses T-cell activation by promoting the generation of mature immunoregulatory dendritic cells (PubMed:19011627). Upon binding to its ligands PVR/CD155 or NECTIN2/CD112, which are expressed on antigen-presenting cells, sends inhibitory signals to the T-cell or NK cell. Mechanistically, interaction with ligand leads to phosphorylation of the cytoplasmic tail by Src family tyrosine kinases such as FYN or LCK, allowing subsequent binding to adapter GRB2 and SHIP1/INPP5D. In turn, inhibits PI3K and MAPK signaling cascades (PubMed:23154388). In addition, associates with beta-arrestin-2/ARRB2 to recruit SHIP1/INPP5D that suppresses autoubiquitination of TRAF6 and subsequently inhibits NF-kappa-B signaling pathway (PubMed:24817116). Also acts as a receptor for NECTIN4 to inhibit NK cell cytotoxicity (PubMed:32503945)","subcellular_location":"Cell membrane","url":"https://www.uniprot.org/uniprotkb/Q495A1/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/TIGIT","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1208,"dependency_fraction":0.0008278145695364238},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/TIGIT","total_profiled":1310},"omim":[{"mim_id":"612859","title":"T-CELL IMMUNORECEPTOR WITH IMMUNOGLOBULIN AND ITIM DOMAINS; TIGIT","url":"https://www.omim.org/entry/612859"},{"mim_id":"606863","title":"THYMOCYTE SELECTION-ASSOCIATED HIGH MOBILITY GROUP BOX; TOX","url":"https://www.omim.org/entry/606863"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"lymphoid tissue","ntpm":36.1}],"url":"https://www.proteinatlas.org/search/TIGIT"},"hgnc":{"alias_symbol":["FLJ39873","DKFZp667A205"],"prev_symbol":["VSIG9","VSTM3"]},"alphafold":{"accession":"Q495A1","domains":[{"cath_id":"2.60.40.10","chopping":"27-128","consensus_level":"high","plddt":96.8675,"start":27,"end":128},{"cath_id":"1.20.5","chopping":"134-181","consensus_level":"high","plddt":76.4206,"start":134,"end":181}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q495A1","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q495A1-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q495A1-F1-predicted_aligned_error_v6.png","plddt_mean":74.62},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=TIGIT","jax_strain_url":"https://www.jax.org/strain/search?query=TIGIT"},"sequence":{"accession":"Q495A1","fasta_url":"https://rest.uniprot.org/uniprotkb/Q495A1.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q495A1/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q495A1"}},"corpus_meta":[{"pmid":"27192565","id":"PMC_27192565","title":"Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation.","date":"2016","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/27192565","citation_count":1693,"is_preprint":false},{"pmid":"25680274","id":"PMC_25680274","title":"Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack.","date":"2015","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/25680274","citation_count":1123,"is_preprint":false},{"pmid":"25465800","id":"PMC_25465800","title":"The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function.","date":"2014","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/25465800","citation_count":968,"is_preprint":false},{"pmid":"29915296","id":"PMC_29915296","title":"Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity.","date":"2018","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/29915296","citation_count":878,"is_preprint":false},{"pmid":"32900861","id":"PMC_32900861","title":"TIGIT in cancer immunotherapy.","date":"2020","source":"Journal for immunotherapy of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/32900861","citation_count":621,"is_preprint":false},{"pmid":"21199897","id":"PMC_21199897","title":"Cutting edge: TIGIT has T cell-intrinsic inhibitory functions.","date":"2011","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/21199897","citation_count":463,"is_preprint":false},{"pmid":"28258695","id":"PMC_28258695","title":"TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy.","date":"2017","source":"Immunological reviews","url":"https://pubmed.ncbi.nlm.nih.gov/28258695","citation_count":375,"is_preprint":false},{"pmid":"37670328","id":"PMC_37670328","title":"Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy.","date":"2023","source":"Journal of hematology & oncology","url":"https://pubmed.ncbi.nlm.nih.gov/37670328","citation_count":282,"is_preprint":false},{"pmid":"21416464","id":"PMC_21416464","title":"Vstm3 is a member of the CD28 family and an important modulator of T-cell function.","date":"2011","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/21416464","citation_count":278,"is_preprint":false},{"pmid":"28883004","id":"PMC_28883004","title":"CD155T/TIGIT Signaling Regulates CD8+ T-cell Metabolism and Promotes Tumor Progression in Human Gastric Cancer.","date":"2017","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/28883004","citation_count":278,"is_preprint":false},{"pmid":"30221069","id":"PMC_30221069","title":"TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM.","date":"2018","source":"Oncoimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/30221069","citation_count":274,"is_preprint":false},{"pmid":"29986909","id":"PMC_29986909","title":"TIGIT immune checkpoint blockade restores CD8+ T-cell immunity against multiple myeloma.","date":"2018","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/29986909","citation_count":245,"is_preprint":false},{"pmid":"27620276","id":"PMC_27620276","title":"Molecular Pathways: Targeting CD96 and TIGIT for Cancer Immunotherapy.","date":"2016","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/27620276","citation_count":191,"is_preprint":false},{"pmid":"31234588","id":"PMC_31234588","title":"DNAM-1 and the TIGIT/PVRIG/TACTILE Axis: Novel Immune Checkpoints for Natural Killer Cell-Based Cancer Immunotherapy.","date":"2019","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/31234588","citation_count":174,"is_preprint":false},{"pmid":"38354701","id":"PMC_38354701","title":"LAG-3, TIM-3, and TIGIT: Distinct functions in immune regulation.","date":"2024","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/38354701","citation_count":173,"is_preprint":false},{"pmid":"37291608","id":"PMC_37291608","title":"Co-inhibition of TIGIT and PD-1/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials.","date":"2023","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/37291608","citation_count":164,"is_preprint":false},{"pmid":"30046006","id":"PMC_30046006","title":"CD226 opposes TIGIT to disrupt Tregs in melanoma.","date":"2018","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/30046006","citation_count":162,"is_preprint":false},{"pmid":"32591463","id":"PMC_32591463","title":"IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma.","date":"2020","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/32591463","citation_count":131,"is_preprint":false},{"pmid":"28900677","id":"PMC_28900677","title":"Tim-3, Lag-3, and TIGIT.","date":"2017","source":"Current topics in microbiology and immunology","url":"https://pubmed.ncbi.nlm.nih.gov/28900677","citation_count":126,"is_preprint":false},{"pmid":"28623459","id":"PMC_28623459","title":"Blockade of CD112R and TIGIT signaling sensitizes human natural killer cell functions.","date":"2017","source":"Cancer immunology, immunotherapy : CII","url":"https://pubmed.ncbi.nlm.nih.gov/28623459","citation_count":125,"is_preprint":false},{"pmid":"33670993","id":"PMC_33670993","title":"TIGIT/CD226 Axis Regulates Anti-Tumor Immunity.","date":"2021","source":"Pharmaceuticals (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/33670993","citation_count":100,"is_preprint":false},{"pmid":"30659053","id":"PMC_30659053","title":"TIGIT and PD-1 Mark Intratumoral T Cells with Reduced Effector Function in B-cell Non-Hodgkin Lymphoma.","date":"2019","source":"Cancer immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/30659053","citation_count":86,"is_preprint":false},{"pmid":"38229100","id":"PMC_38229100","title":"Targeting TIGIT for cancer immunotherapy: recent advances and future directions.","date":"2024","source":"Biomarker research","url":"https://pubmed.ncbi.nlm.nih.gov/38229100","citation_count":77,"is_preprint":false},{"pmid":"38181797","id":"PMC_38181797","title":"Integrative analysis of neuroblastoma by single-cell RNA sequencing identifies the NECTIN2-TIGIT axis as a target for immunotherapy.","date":"2024","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/38181797","citation_count":75,"is_preprint":false},{"pmid":"34628052","id":"PMC_34628052","title":"PD-1 and TIGIT downregulation distinctly affect the effector and early memory phenotypes of CD19-targeting CAR T cells.","date":"2021","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/34628052","citation_count":74,"is_preprint":false},{"pmid":"36549780","id":"PMC_36549780","title":"TIGIT blockade repolarizes AML-associated TIGIT+ M2 macrophages to an M1 phenotype and increases CD47-mediated phagocytosis.","date":"2022","source":"Journal for immunotherapy of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/36549780","citation_count":71,"is_preprint":false},{"pmid":"35729552","id":"PMC_35729552","title":"Blocking TIGIT/CD155 signalling reverses CD8+ T cell exhaustion and enhances the antitumor activity in cervical cancer.","date":"2022","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35729552","citation_count":69,"is_preprint":false},{"pmid":"33750787","id":"PMC_33750787","title":"Implication of TIGIT+ human memory B cells in immune regulation.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/33750787","citation_count":67,"is_preprint":false},{"pmid":"33188038","id":"PMC_33188038","title":"PD-1 and TIGIT coexpression identifies a circulating CD8 T cell subset predictive of response to anti-PD-1 therapy.","date":"2020","source":"Journal for immunotherapy of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/33188038","citation_count":63,"is_preprint":false},{"pmid":"31500665","id":"PMC_31500665","title":"A TIGIT-based chimeric co-stimulatory switch receptor improves T-cell anti-tumor function.","date":"2019","source":"Journal for immunotherapy of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/31500665","citation_count":62,"is_preprint":false},{"pmid":"30733837","id":"PMC_30733837","title":"Patterns of TIGIT Expression in Lymphatic Tissue, Inflammation, and Cancer.","date":"2019","source":"Disease markers","url":"https://pubmed.ncbi.nlm.nih.gov/30733837","citation_count":61,"is_preprint":false},{"pmid":"34545095","id":"PMC_34545095","title":"Profiling the inhibitory receptors LAG-3, TIM-3, and TIGIT in renal cell carcinoma reveals malignancy.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/34545095","citation_count":59,"is_preprint":false},{"pmid":"32489646","id":"PMC_32489646","title":"Targeting the \"PVR-TIGIT axis\" with immune checkpoint therapies.","date":"2020","source":"F1000Research","url":"https://pubmed.ncbi.nlm.nih.gov/32489646","citation_count":57,"is_preprint":false},{"pmid":"38596295","id":"PMC_38596295","title":"Promising immunotherapy targets: TIM3, LAG3, and TIGIT joined the party.","date":"2024","source":"Molecular therapy. Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/38596295","citation_count":57,"is_preprint":false},{"pmid":"32668241","id":"PMC_32668241","title":"Checkpoint Receptor TIGIT Expressed on Tim-1+ B Cells Regulates Tissue Inflammation.","date":"2020","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/32668241","citation_count":56,"is_preprint":false},{"pmid":"37768658","id":"PMC_37768658","title":"Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors: A Phase 1a/1b Nonrandomized Controlled Trial.","date":"2023","source":"JAMA oncology","url":"https://pubmed.ncbi.nlm.nih.gov/37768658","citation_count":54,"is_preprint":false},{"pmid":"28108989","id":"PMC_28108989","title":"TIGIT signalling pathway negatively regulates CD4+ T-cell responses in systemic lupus erythematosus.","date":"2017","source":"Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/28108989","citation_count":54,"is_preprint":false},{"pmid":"34025646","id":"PMC_34025646","title":"TIGIT and PD-1 Immune Checkpoint Pathways Are Associated With Patient Outcome and Anti-Tumor Immunity in Glioblastoma.","date":"2021","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/34025646","citation_count":54,"is_preprint":false},{"pmid":"38779918","id":"PMC_38779918","title":"Platelet-mediated circulating tumor cell evasion from natural killer cell killing through immune checkpoint CD155-TIGIT.","date":"2024","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/38779918","citation_count":52,"is_preprint":false},{"pmid":"31485637","id":"PMC_31485637","title":"Expression of TIGIT/CD155 and correlations with clinical pathological features in human hepatocellular carcinoma.","date":"2019","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/31485637","citation_count":52,"is_preprint":false},{"pmid":"35292828","id":"PMC_35292828","title":"Targeting PD-L1 and TIGIT could restore intratumoral CD8 T cell function in human colorectal cancer.","date":"2022","source":"Cancer immunology, immunotherapy : CII","url":"https://pubmed.ncbi.nlm.nih.gov/35292828","citation_count":50,"is_preprint":false},{"pmid":"34694361","id":"PMC_34694361","title":"DNAM-1 versus TIGIT: competitive roles in tumor immunity and inflammatory responses.","date":"2021","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/34694361","citation_count":48,"is_preprint":false},{"pmid":"36689623","id":"PMC_36689623","title":"Tissue-Resident Memory T Cells in Pancreatic Ductal Adenocarcinoma Coexpress PD-1 and TIGIT and Functional Inhibition Is Reversible by Dual Antibody Blockade.","date":"2023","source":"Cancer immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/36689623","citation_count":47,"is_preprint":false},{"pmid":"37596248","id":"PMC_37596248","title":"TIGIT can inhibit T cell activation via ligation-induced nanoclusters, independent of CD226 co-stimulation.","date":"2023","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/37596248","citation_count":45,"is_preprint":false},{"pmid":"38216949","id":"PMC_38216949","title":"The immune checkpoint TIGIT/CD155 promotes the exhaustion of CD8 + T cells in TNBC through glucose metabolic reprogramming mediated by PI3K/AKT/mTOR signaling.","date":"2024","source":"Cell communication and signaling : CCS","url":"https://pubmed.ncbi.nlm.nih.gov/38216949","citation_count":44,"is_preprint":false},{"pmid":"28438433","id":"PMC_28438433","title":"Contribution of inhibitory receptor TIGIT to NK cell education.","date":"2017","source":"Journal of autoimmunity","url":"https://pubmed.ncbi.nlm.nih.gov/28438433","citation_count":44,"is_preprint":false},{"pmid":"33298247","id":"PMC_33298247","title":"Hitting the complexity of the TIGIT-CD96-CD112R-CD226 axis for next-generation cancer immunotherapy.","date":"2021","source":"BMB reports","url":"https://pubmed.ncbi.nlm.nih.gov/33298247","citation_count":44,"is_preprint":false},{"pmid":"32212317","id":"PMC_32212317","title":"TIGIT enhances CD4+ regulatory T-cell response and mediates immune suppression in a murine ovarian cancer model.","date":"2020","source":"Cancer medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32212317","citation_count":44,"is_preprint":false},{"pmid":"35656508","id":"PMC_35656508","title":"Update in TIGIT Immune-Checkpoint Role in Cancer.","date":"2022","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/35656508","citation_count":43,"is_preprint":false},{"pmid":"34795387","id":"PMC_34795387","title":"A pan-cancer analysis revealing the role of TIGIT in tumor microenvironment.","date":"2021","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/34795387","citation_count":41,"is_preprint":false},{"pmid":"32774695","id":"PMC_32774695","title":"Immune checkpoint targeting TIGIT in hepatocellular carcinoma.","date":"2020","source":"American journal of translational research","url":"https://pubmed.ncbi.nlm.nih.gov/32774695","citation_count":40,"is_preprint":false},{"pmid":"32172208","id":"PMC_32172208","title":"The relationship between TIGIT+ regulatory T cells and autoimmune disease.","date":"2020","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/32172208","citation_count":38,"is_preprint":false},{"pmid":"35326415","id":"PMC_35326415","title":"Tissue-Specific Expression of TIGIT, PD-1, TIM-3, and CD39 by γδ T Cells in Ovarian Cancer.","date":"2022","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/35326415","citation_count":38,"is_preprint":false},{"pmid":"27016609","id":"PMC_27016609","title":"TIGIT Enhances Antigen-Specific Th2 Recall Responses and Allergic Disease.","date":"2016","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/27016609","citation_count":38,"is_preprint":false},{"pmid":"32782142","id":"PMC_32782142","title":"A novel bispecific nanobody with PD-L1/TIGIT dual immune checkpoint blockade.","date":"2020","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/32782142","citation_count":38,"is_preprint":false},{"pmid":"33117369","id":"PMC_33117369","title":"Effective Anti-tumor Response by TIGIT Blockade Associated With FcγR Engagement and Myeloid Cell Activation.","date":"2020","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/33117369","citation_count":37,"is_preprint":false},{"pmid":"36250467","id":"PMC_36250467","title":"Impaired TIGIT expression on B cells drives circulating follicular helper T cell expansion in multiple sclerosis.","date":"2022","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/36250467","citation_count":36,"is_preprint":false},{"pmid":"33408249","id":"PMC_33408249","title":"PET Imaging of TIGIT Expression on Tumor-Infiltrating Lymphocytes.","date":"2021","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/33408249","citation_count":34,"is_preprint":false},{"pmid":"30514251","id":"PMC_30514251","title":"Expression of the immune checkpoint receptor TIGIT in Hodgkin's lymphoma.","date":"2018","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/30514251","citation_count":33,"is_preprint":false},{"pmid":"34659197","id":"PMC_34659197","title":"TIGIT Induces (CD3+) T Cell Dysfunction in Colorectal Cancer by Inhibiting Glucose Metabolism.","date":"2021","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/34659197","citation_count":33,"is_preprint":false},{"pmid":"31005675","id":"PMC_31005675","title":"Treatment of murine lupus with TIGIT-Ig.","date":"2019","source":"Clinical immunology (Orlando, Fla.)","url":"https://pubmed.ncbi.nlm.nih.gov/31005675","citation_count":30,"is_preprint":false},{"pmid":"32802845","id":"PMC_32802845","title":"Characteristic of TIGIT and DNAM-1 Expression on Foxp3+ γδ T Cells in AML Patients.","date":"2020","source":"BioMed research international","url":"https://pubmed.ncbi.nlm.nih.gov/32802845","citation_count":29,"is_preprint":false},{"pmid":"30638415","id":"PMC_30638415","title":"Divergent LAG-3 versus BTLA, TIGIT, and FCRL3 expression in Sézary syndrome.","date":"2019","source":"Leukemia & lymphoma","url":"https://pubmed.ncbi.nlm.nih.gov/30638415","citation_count":27,"is_preprint":false},{"pmid":"35273617","id":"PMC_35273617","title":"CD226 and TIGIT Cooperate in the Differentiation and Maturation of Human Tfh Cells.","date":"2022","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35273617","citation_count":26,"is_preprint":false},{"pmid":"32397769","id":"PMC_32397769","title":"Upregulation of TIGIT and PD-1 in Colorectal Cancer with Mismatch-repair Deficiency.","date":"2020","source":"Immunological investigations","url":"https://pubmed.ncbi.nlm.nih.gov/32397769","citation_count":26,"is_preprint":false},{"pmid":"34707863","id":"PMC_34707863","title":"TIGIT blockade enhances NK cell activity against autologous HIV-1-infected CD4+ T cells.","date":"2021","source":"Clinical & translational immunology","url":"https://pubmed.ncbi.nlm.nih.gov/34707863","citation_count":25,"is_preprint":false},{"pmid":"38008725","id":"PMC_38008725","title":"GITR and TIGIT immunotherapy provokes divergent multicellular responses in the tumor microenvironment of gastrointestinal cancers.","date":"2023","source":"Genome medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38008725","citation_count":24,"is_preprint":false},{"pmid":"36747315","id":"PMC_36747315","title":"Immune Checkpoint Molecule TIGIT Regulates Kidney T Cell Functions and Contributes to AKI.","date":"2023","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/36747315","citation_count":24,"is_preprint":false},{"pmid":"35412226","id":"PMC_35412226","title":"Clinical Development of Anti-TIGIT Antibodies for Immunotherapy of Cancer.","date":"2022","source":"Current oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/35412226","citation_count":24,"is_preprint":false},{"pmid":"35433470","id":"PMC_35433470","title":"Role of CD155/TIGIT in Digestive Cancers: Promising Cancer Target for Immunotherapy.","date":"2022","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/35433470","citation_count":24,"is_preprint":false},{"pmid":"36636263","id":"PMC_36636263","title":"Tiragolumab (Anti-TIGIT) in SCLC: Skyscraper-02, a Towering Inferno.","date":"2023","source":"Lung Cancer (Auckland, N.Z.)","url":"https://pubmed.ncbi.nlm.nih.gov/36636263","citation_count":24,"is_preprint":false},{"pmid":"39591972","id":"PMC_39591972","title":"Analysis of PD1, LAG3, TIGIT, and TIM3 expression in human lung adenocarcinoma reveals a 25-gene signature predicting immunotherapy response.","date":"2024","source":"Cell reports. Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/39591972","citation_count":23,"is_preprint":false},{"pmid":"36544779","id":"PMC_36544779","title":"Correlation of the TIGIT-PVR immune checkpoint axis with clinicopathological features in triple-negative breast cancer.","date":"2022","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/36544779","citation_count":23,"is_preprint":false},{"pmid":"37262959","id":"PMC_37262959","title":"TIGIT: An emerging immune checkpoint target for immunotherapy in autoimmune disease and cancer.","date":"2023","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/37262959","citation_count":22,"is_preprint":false},{"pmid":"36497240","id":"PMC_36497240","title":"The Dual Blockade of the TIGIT and PD-1/PD-L1 Pathway as a New Hope for Ovarian Cancer Patients.","date":"2022","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/36497240","citation_count":22,"is_preprint":false},{"pmid":"37161050","id":"PMC_37161050","title":"Anti-human-TIGIT agonistic antibody ameliorates autoimmune diseases by inhibiting Tfh and Tph cells and enhancing Treg cells.","date":"2023","source":"Communications biology","url":"https://pubmed.ncbi.nlm.nih.gov/37161050","citation_count":22,"is_preprint":false},{"pmid":"31108170","id":"PMC_31108170","title":"Stress-elicited glucocorticoid receptor signaling upregulates TIGIT in innate-like invariant T lymphocytes.","date":"2019","source":"Brain, behavior, and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/31108170","citation_count":21,"is_preprint":false},{"pmid":"39406740","id":"PMC_39406740","title":"TGF-β-mediated crosstalk between TIGIT+ Tregs and CD226+CD8+ T cells in the progression and remission of type 1 diabetes.","date":"2024","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/39406740","citation_count":19,"is_preprint":false},{"pmid":"34638729","id":"PMC_34638729","title":"A Systematic Review and Meta-Analysis on the Significance of TIGIT in Solid Cancers: Dual TIGIT/PD-1 Blockade to Overcome Immune-Resistance in Solid Cancers.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34638729","citation_count":19,"is_preprint":false},{"pmid":"33744939","id":"PMC_33744939","title":"Correlation Between TIGIT Expression on CD8+ T Cells and Higher Cytotoxic Capacity.","date":"2021","source":"The Journal of infectious diseases","url":"https://pubmed.ncbi.nlm.nih.gov/33744939","citation_count":18,"is_preprint":false},{"pmid":"37542773","id":"PMC_37542773","title":"Molecular and structural basis of TIGIT: Nectin-4 interaction, a recently discovered pathway crucial for cancer immunotherapy.","date":"2023","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/37542773","citation_count":18,"is_preprint":false},{"pmid":"33782477","id":"PMC_33782477","title":"A novel scoring system for TIGIT expression in classic Hodgkin lymphoma.","date":"2021","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/33782477","citation_count":18,"is_preprint":false},{"pmid":"35651622","id":"PMC_35651622","title":"Co-Expression of TIGIT and Helios Marks Immunosenescent CD8+ T Cells During Aging.","date":"2022","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35651622","citation_count":16,"is_preprint":false},{"pmid":"36512425","id":"PMC_36512425","title":"TIGIT inhibition and lenalidomide synergistically promote antimyeloma immune responses after stem cell transplantation in mice.","date":"2023","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/36512425","citation_count":16,"is_preprint":false},{"pmid":"35090381","id":"PMC_35090381","title":"Structural and functional characterization of a monoclonal antibody blocking TIGIT.","date":"2022","source":"mAbs","url":"https://pubmed.ncbi.nlm.nih.gov/35090381","citation_count":16,"is_preprint":false},{"pmid":"31883787","id":"PMC_31883787","title":"Recovery of CD226-TIGIT+FoxP3+ and CD226-TIGIT-FoxP3+ regulatory T cells contributes to clinical remission from active stage in ulcerative colitis patients.","date":"2019","source":"Immunology letters","url":"https://pubmed.ncbi.nlm.nih.gov/31883787","citation_count":16,"is_preprint":false},{"pmid":"39187595","id":"PMC_39187595","title":"Clinical response and pathway-specific correlates following TIGIT-LAG3 blockade in myeloma: the MyCheckpoint randomized clinical trial.","date":"2024","source":"Nature cancer","url":"https://pubmed.ncbi.nlm.nih.gov/39187595","citation_count":15,"is_preprint":false},{"pmid":"32665122","id":"PMC_32665122","title":"TIM-3 and TIGIT are possible immune checkpoint targets in patients with bladder cancer.","date":"2020","source":"Urologic oncology","url":"https://pubmed.ncbi.nlm.nih.gov/32665122","citation_count":15,"is_preprint":false},{"pmid":"37364933","id":"PMC_37364933","title":"TIGIT is a key inhibitory checkpoint receptor in lymphoma.","date":"2023","source":"Journal for immunotherapy of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/37364933","citation_count":14,"is_preprint":false},{"pmid":"37036426","id":"PMC_37036426","title":"TIGIT mediates activation-induced cell death of ILC2s during chronic airway allergy.","date":"2023","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/37036426","citation_count":14,"is_preprint":false},{"pmid":"37799715","id":"PMC_37799715","title":"Development and evaluation of nanobody tracers for noninvasive nuclear imaging of the immune-checkpoint TIGIT.","date":"2023","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/37799715","citation_count":14,"is_preprint":false},{"pmid":"35265633","id":"PMC_35265633","title":"TIGIT Signaling Pathway Regulates Natural Killer Cell Function in Chronic Hepatitis B Virus Infection.","date":"2022","source":"Frontiers in medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35265633","citation_count":13,"is_preprint":false},{"pmid":"31423216","id":"PMC_31423216","title":"Expression of the immune checkpoint receptor TIGIT in seminoma.","date":"2019","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/31423216","citation_count":13,"is_preprint":false},{"pmid":"38745667","id":"PMC_38745667","title":"Human regulatory memory B cells defined by expression of TIM-1 and TIGIT are dysfunctional in multiple sclerosis.","date":"2024","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/38745667","citation_count":12,"is_preprint":false},{"pmid":"40567374","id":"PMC_40567374","title":"Tiragolumab and TIGIT: pioneering the next era of cancer immunotherapy.","date":"2025","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/40567374","citation_count":12,"is_preprint":false},{"pmid":"37359558","id":"PMC_37359558","title":"Self-delivery of TIGIT-blocking scFv enhances CAR-T immunotherapy in solid tumors.","date":"2023","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/37359558","citation_count":12,"is_preprint":false},{"pmid":"37444427","id":"PMC_37444427","title":"Combined Blockade of TIGIT and PD-L1 Enhances Anti-Neuroblastoma Efficacy of GD2-Directed Immunotherapy with Dinutuximab Beta.","date":"2023","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/37444427","citation_count":12,"is_preprint":false},{"pmid":"37129788","id":"PMC_37129788","title":"Peptide-based PET imaging agent of tumor TIGIT expression.","date":"2023","source":"EJNMMI research","url":"https://pubmed.ncbi.nlm.nih.gov/37129788","citation_count":11,"is_preprint":false},{"pmid":"36655432","id":"PMC_36655432","title":"The immunomodulatory molecule TIGIT is expressed by chronic lymphocytic leukemia cells and contributes to anergy.","date":"2023","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/36655432","citation_count":11,"is_preprint":false},{"pmid":"38527557","id":"PMC_38527557","title":"Dual targeting of TIGIT and PD-1 with a novel small molecule for cancer immunotherapy.","date":"2024","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/38527557","citation_count":11,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":48783,"output_tokens":5612,"usd":0.115265},"stage2":{"model":"claude-opus-4-6","input_tokens":9268,"output_tokens":3581,"usd":0.203797},"total_usd":0.319062,"stage1_batch_id":"msgbatch_01RPbVc9PDH9zQmYK5Hs6srm","stage2_batch_id":"msgbatch_01JVbVLzeKN2yVrsGp3zC8aM","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2011,\n      \"finding\": \"TIGIT has T cell-intrinsic inhibitory functions independent of APCs; agonistic anti-TIGIT antibody directly attenuates TCR-driven activation signals in T cells, and TIGIT-deficient mice show hyperproliferative T cell responses and increased susceptibility to autoimmunity.\",\n      \"method\": \"Agonistic anti-TIGIT antibody stimulation, microarray analysis of stimulated T cells, TIGIT knockout mouse model\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean KO phenotype plus agonistic antibody functional dissection, replicated across multiple experimental approaches in one study\",\n      \"pmids\": [\"21199897\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"TIGIT (VSTM3) binds to nectin-family ligands CD155 (PVR) and CD112, which are also ligands for the activating receptor CD226, establishing a regulatory network analogous to CD28/CTLA-4; soluble VSTM3 attenuates T cell responses in vitro and in vivo, and VSTM3-deficient animals are more sensitive to autoimmune challenges.\",\n      \"method\": \"Ligand binding assays, soluble fusion protein treatment in vitro and in vivo, gene-deficient mouse autoimmune models\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (binding, functional, KO), confirmed in vivo\",\n      \"pmids\": [\"21416464\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"TIGIT functions as a co-inhibitory receptor that limits CD8+ T cell effector function in tumors and chronic viral infection; CD226 dimerization is disrupted by direct TIGIT–CD226 interaction in cis, and antibody co-blockade of TIGIT and PD-L1 synergistically enhances CD8+ T cell responses.\",\n      \"method\": \"Antibody blockade in murine tumor and viral infection models, assessment of CD226 dimerization upon TIGIT interaction\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple in vivo models plus direct molecular interaction data, strong epistasis evidence\",\n      \"pmids\": [\"25465800\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"The Fap2 protein of Fusobacterium nucleatum directly interacts with human TIGIT on NK cells and T cells, inhibiting NK cell cytotoxicity and T cell activity, thereby enabling tumor immune evasion.\",\n      \"method\": \"F. nucleatum mutant library screen, direct protein interaction assays, NK cell cytotoxicity assays\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mutant library screen identifying specific bacterial protein, functional cytotoxicity assays, replicated across multiple tumor types\",\n      \"pmids\": [\"25680274\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"TIGIT enhances Th2 recall responses and allergic disease; its interaction with CD155 on dendritic cells promotes Th2 polarization, and in vivo TIGIT blockade suppresses hallmarks of allergic airway disease including lung eosinophilia and IgE production.\",\n      \"method\": \"In vitro Th2 polarization cultures, in vivo allergic airway disease model with TIGIT blockade\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple in vitro and in vivo readouts, single lab\",\n      \"pmids\": [\"27016609\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"TIGIT-CD155 interaction promotes NK cell functional maturation (education) in a MHC-I-independent manner; TIGIT+ NK cells from CD155-deficient hosts show functional impairment, and TIGIT deficiency impairs missing-self recognition independently of CD226.\",\n      \"method\": \"TIGIT-KO and CD155-KO mouse models, NK cell functional assays, missing-self rejection assays\",\n      \"journal\": \"Journal of autoimmunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — KO of both receptor and ligand with specific phenotypic readouts, mechanistically dissected from CD226\",\n      \"pmids\": [\"28438433\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"CD155/TIGIT signaling inhibits CD8+ T cell metabolism and effector function in gastric cancer; CD155 on gastric cancer cells binds TIGIT and deprives T cells of glucose, impairing IFNγ production, an effect reversed by TIGIT blockade or additional glucose.\",\n      \"method\": \"T cell-tumor coculture assays, CD155 silencing/overexpression, glucose supplementation rescue, in vivo tumor model\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple genetic and pharmacologic interventions with consistent metabolic and functional phenotype readouts\",\n      \"pmids\": [\"28883004\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"TIGIT is highly expressed on NK cells in tumor-bearing mice and cancer patients; TIGIT blockade prevents NK cell exhaustion and promotes NK cell-dependent tumor immunity and CD8+ T cell tumor-specific immunity.\",\n      \"method\": \"TIGIT antibody blockade in multiple mouse tumor models, NK cell depletion experiments, flow cytometry\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple tumor models, NK depletion epistasis, replicated findings\",\n      \"pmids\": [\"29915296\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"TIGIT on CD4+ Tregs in melanoma augments Treg suppressive function and stability; high TIGIT expression with low CD226 on Tregs enhances their suppressive capacity, while CD226 expression disrupts Treg suppression.\",\n      \"method\": \"Flow cytometry of patient tumor samples, functional Treg suppression assays, TIGIT/CD226 expression analysis\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — functional correlation data with patient samples, single lab\",\n      \"pmids\": [\"30046006\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Glucocorticoid receptor (GR) signaling directly upregulates TIGIT expression on T cells and iNKT cells; stress-induced TIGIT upregulation is reversed by the GR antagonist RU486, and Lck-Cre GR knockout mice fail to upregulate TIGIT under stress.\",\n      \"method\": \"GR antagonist treatment, chemical sympathectomy, Cre/Lox GR conditional knockout, corticosterone administration in vitro and in vivo\",\n      \"journal\": \"Brain, behavior, and immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — conditional KO plus pharmacological intervention, multiple cell types and models\",\n      \"pmids\": [\"31108170\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Membrane-bound CD155 on tumor cells triggers CD226 internalization and degradation on NK cells, resulting in decreased NK cell-mediated tumor reactivity; IL-15 upregulates both TIGIT and CD226 on tumor-infiltrating NK cells and, combined with TIGIT blockade, increases NK cell cytotoxicity.\",\n      \"method\": \"CD226 internalization assays, TIGIT-specific NK cell transfer, mouse melanoma metastasis models, flow cytometry\",\n      \"journal\": \"Clinical cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic dissection of CD226 degradation, genetic (TIGIT-KO NK cells), and pharmacologic approaches\",\n      \"pmids\": [\"32591463\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"TIGIT on memory B cells suppresses immune responses by directly inhibiting T cell proliferation and by arresting pro-inflammatory dendritic cell function via TIGIT/CD155 interactions; TIGIT+ memory B cells also express IL-10, TGF-β1, granzyme B, PD-L1, CD39/CD73, and TIM-1.\",\n      \"method\": \"TIGIT+ B cell isolation, co-culture with T cells and dendritic cells, TIGIT blockade experiments, flow cytometry\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — functional co-culture assays with defined mechanistic readouts, single lab\",\n      \"pmids\": [\"33750787\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"B cell-specific TIGIT deletion causes spontaneous CNS inflammation and paralysis; Tim-1 signaling-dependent TIGIT expression on B cells is essential for maintaining CNS-specific tolerance.\",\n      \"method\": \"B cell-specific TIGIT conditional knockout mice, transcriptomic analysis, in vivo neuroinflammation model\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean conditional KO with specific CNS inflammatory phenotype, transcriptomic analysis\",\n      \"pmids\": [\"32668241\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Anti-TIGIT antibody therapeutic effect requires functional Fc binding to FcγRs on myeloid cells; TIGIT blockade does not deplete Tregs but instead induces 'reverse activating signals' through FcγRs causing cytokine/chemokine expression and a granzyme B/perforin response distinct from anti-PD-1.\",\n      \"method\": \"Mouse tumor models with Fc-functional vs. Fc-null anti-TIGIT antibodies, myeloid cell analysis, cytokine profiling\",\n      \"journal\": \"Frontiers in immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic dissection of Fc requirement in vivo, single lab\",\n      \"pmids\": [\"33117369\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"TIGIT blockade in AML repolarizes TIGIT+ M2 leukemia-associated macrophages to M1 phenotype, increases secretion of M1-associated cytokines, and augments anti-CD47-mediated phagocytosis of AML cells.\",\n      \"method\": \"In vitro TIGIT blockade on primary LAMs, flow cytometry, cytokine measurement, phagocytosis assays\",\n      \"journal\": \"Journal for immunotherapy of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — functional in vitro assays with primary patient-derived macrophages, single lab\",\n      \"pmids\": [\"36549780\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"TIGIT, upon binding to CD155, is phosphorylated and recruits SHIP-1, which inhibits NF-κB and ERK activation in CD8+ T cells, resulting in reduced cytokine production; TIGIT blockade attenuates SHIP-1 inhibitory effects and restores NF-κB and ERK signaling.\",\n      \"method\": \"Western blotting for NF-κB and ERK pathway after TIGIT/CD155 blockade, phosphorylation assays, in vivo tumor model\",\n      \"journal\": \"Journal of translational medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — defined intracellular signaling pathway with western blot evidence, in vivo confirmation\",\n      \"pmids\": [\"35729552\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Impaired TIGIT expression on MS-derived B cells is mediated by dysregulation of transcription factor TCF4; TIGIT on B cells suppresses proliferation of IL-17-producing circulating follicular helper T cells via the TIGIT/CD155 axis.\",\n      \"method\": \"Comparative gene expression analysis, co-culture assays of B cells and cTfh cells, TCF4 dysregulation analysis\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — TCF4-mediated transcriptional mechanism identified, functional TIGIT/CD155 suppression demonstrated\",\n      \"pmids\": [\"36250467\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"TIGIT ligation with CD155 causes TIGIT to reorganize into dense nanoclusters at the immune synapse that coalesce with TCR-rich clusters; this reduces cytokine secretion in a manner dependent on TIGIT's intracellular ITT-like signalling motif, independent of CD226 co-expression.\",\n      \"method\": \"Super-resolution microscopy, immune synapse imaging, ITT-motif mutagenesis, cytokine secretion assays on matched tumor/blood samples\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — super-resolution structural imaging combined with mutagenesis of signaling motif and functional readout, mechanistically rigorous\",\n      \"pmids\": [\"37596248\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"TIGIT mediates activation-induced cell death (AICD) of ILC2s during chronic airway allergy; ILC2 interaction with CD155 on macrophages promotes apoptosis of TIGIT+ ILC2s, and genetic ablation of Tigit or TIGIT blockade promotes ILC2 survival and worsens chronic allergic inflammation.\",\n      \"method\": \"TIGIT lineage tracer mice, ILC2 apoptosis assays, Tigit knockout mice, anti-TIGIT antagonistic antibody treatment, chromatin accessibility analysis\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — lineage tracing, KO, and pharmacologic blockade with mechanistic chromatin analysis\",\n      \"pmids\": [\"37036426\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"TIGIT interacts with nectin-4 as a novel ligand through the membrane-distal ectodomain of nectin-4; this interaction is weaker than TIGIT:nectin-2 binding and inhibits NK cell cytotoxicity; structure-guided mutagenesis mapped the nectin-4 binding interface on TIGIT.\",\n      \"method\": \"Surface plasmon resonance, structure-guided mutagenesis, NK cell cytotoxicity assays\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 — biophysical binding assay with mutagenesis, single lab\",\n      \"pmids\": [\"37542773\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Crystal structure of anti-TIGIT antibody MG1131 bound to TIGIT shows that MG1131 blocks the PVR-TIGIT interaction interface; functional assays confirm MG1131 increases NK cell-mediated tumor killing, inhibits Treg suppression, and restores IFNγ secretion from myeloma patient PBMCs.\",\n      \"method\": \"X-ray crystallography, competitive binding assays, NK cytotoxicity assays, Treg suppression assays\",\n      \"journal\": \"mAbs\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure with functional validation across multiple cell types\",\n      \"pmids\": [\"35090381\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Anti-TIGIT agonistic antibody suppresses activation of follicular helper T (Tfh) and peripheral helper T (Tph) cells that highly express TIGIT, and enhances suppressive function of naïve regulatory T cells, in human TIGIT knock-in mice.\",\n      \"method\": \"Anti-hu-TIGIT agonistic mAb generation, hu-TIGIT knock-in mouse model, CD4+ T cell functional assays\",\n      \"journal\": \"Communications biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — humanized knock-in model with agonistic antibody, functional cell assays, single lab\",\n      \"pmids\": [\"37161050\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Anti-TIGIT activity against myeloma depends on FcγR binding; anti-TIGIT antibodies engaging FcγRs synergize with lenalidomide in a CD8+ T cell-dependent manner post-transplantation, suppressing T cell exhaustion and enhancing effector function specifically in the bone marrow tumor microenvironment.\",\n      \"method\": \"Fc-functional vs. Fc-null anti-TIGIT comparison, CRBN mouse model, CD8+ T cell depletion, bone marrow CD8 T cell phenotyping\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — FcγR requirement mechanistically established with isotype controls plus CD8 depletion epistasis, in vivo\",\n      \"pmids\": [\"36512425\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"CD155/TIGIT signaling disrupts glucose metabolism of CD8+ T cells in TNBC by suppressing PI3K/AKT/mTOR signaling pathway activation, reducing glycolytic-related proteins and cytokine production; TIGIT blockade restores PI3K/AKT/mTOR activation and cytokine production.\",\n      \"method\": \"Western blotting for PI3K/AKT/mTOR pathway, glucose/lactate assays, in vitro and in vivo TIGIT blockade\",\n      \"journal\": \"Cell communication and signaling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — defined intracellular pathway with metabolic readouts, in vivo confirmation, single lab\",\n      \"pmids\": [\"38216949\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"CD155 on CTCs is transcriptionally regulated by the FAK/JNK/c-Jun cascade in a platelet contact-dependent manner; CD155 on CTCs inhibits NK cell cytotoxicity specifically by engaging TIGIT (but not CD96 or DNAM-1), and TIGIT antibody blockade restores NK immunosurveillance and reduces tumor metastasis.\",\n      \"method\": \"Competition assays, cytotoxicity experiments, FAK/JNK/c-Jun pathway analysis, in vitro/ex vivo/in vivo NK assays\",\n      \"journal\": \"Hepatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — receptor specificity dissected by competition assays, FAK/JNK/c-Jun cascade identified, in vivo validation\",\n      \"pmids\": [\"38779918\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"TIGIT+CCR7- Tregs inhibit CD226+CCR7-CD8+ cytotoxic T cells via TGF-β signaling in type 1 diabetes; CD226 inhibition in mouse models postpones insulitis onset and reduces hyperglycemia severity.\",\n      \"method\": \"Single-cell RNA sequencing, cell communication analysis, in vitro functional assays, cyclophosphamide- and STZ-induced mouse diabetes models with CD226 inhibition\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — scRNA-seq cell communication plus in vitro TGF-β assays and in vivo CD226 inhibition, single lab\",\n      \"pmids\": [\"39406740\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"TIGIT is an inhibitory immune checkpoint receptor expressed on T cells, NK cells, Tregs, and B cells that suppresses immune activation through multiple mechanisms: direct cell-intrinsic signaling via its intracellular ITT-like motif (forming TCR-proximal nanoclusters and recruiting SHIP-1 to inhibit NF-κB/ERK), competition with the activating receptor CD226 for shared ligands CD155 (PVR) and CD112 (nectin-2), CD226 internalization/degradation triggered by membrane-bound CD155, FcγR-dependent myeloid cell modulation by anti-TIGIT antibodies, promotion of Treg suppressive function, metabolic suppression of CD8+ T cells via the PI3K/AKT/mTOR and glucose utilization pathways, and induction of ILC2 activation-induced cell death through CD155 on macrophages; its expression is transcriptionally regulated by glucocorticoid receptor signaling and TCF4, and its ligand binding extends to nectin-4, while bacterial Fap2 protein exploitation of TIGIT represents an additional tumor immune evasion mechanism.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"TIGIT is an inhibitory immune checkpoint receptor expressed on T cells, NK cells, regulatory T cells, ILC2s, and B cells that restrains immune activation through multiple convergent mechanisms: cell-intrinsic signaling via its ITT-like motif that recruits SHIP-1 to suppress NF-κB/ERK pathways, competitive antagonism of the co-activating receptor CD226 for shared nectin-family ligands (CD155/PVR, CD112, nectin-4), and direct disruption of CD226 homodimerization in cis [PMID:21199897, PMID:25465800, PMID:35729552, PMID:37596248]. Upon CD155 engagement, TIGIT reorganizes into TCR-proximal nanoclusters at the immune synapse to dampen cytokine secretion, suppresses CD8+ T cell glucose metabolism via inhibition of PI3K/AKT/mTOR signaling, and promotes activation-induced cell death of ILC2s, while on Tregs it enhances suppressive capacity and stability [PMID:37596248, PMID:28883004, PMID:38216949, PMID:37036426, PMID:30046006]. TIGIT also functions on B cells to maintain tolerance—B cell-specific TIGIT deletion causes spontaneous CNS inflammation—and its transcriptional regulation involves glucocorticoid receptor signaling and TCF4 [PMID:32668241, PMID:31108170, PMID:36250467]. The Fusobacterium nucleatum virulence factor Fap2 directly engages TIGIT to inhibit NK and T cell cytotoxicity, representing a microbial immune evasion strategy, while therapeutic anti-TIGIT antibodies exert effects that depend critically on Fc-FcγR engagement with myeloid cells [PMID:25680274, PMID:33117369, PMID:36512425].\",\n  \"teleology\": [\n    {\n      \"year\": 2011,\n      \"claim\": \"Establishing that TIGIT functions as a T cell-intrinsic co-inhibitory receptor—not merely an APC-targeting molecule—resolved the question of whether TIGIT directly suppresses T cell activation, showing that TIGIT-deficient mice develop hyperproliferative T cell responses and autoimmunity susceptibility.\",\n      \"evidence\": \"Agonistic anti-TIGIT antibody stimulation, microarray analysis, and TIGIT knockout mouse model\",\n      \"pmids\": [\"21199897\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Intracellular signaling pathway downstream of TIGIT not yet identified\", \"Whether TIGIT inhibition operates on cell types beyond T cells unclear\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Identifying CD155 and CD112 as shared ligands for both TIGIT and the activating receptor CD226 established the TIGIT/CD226 regulatory axis as a paradigm analogous to CTLA-4/CD28, explaining how TIGIT achieves inhibition partly through ligand competition.\",\n      \"evidence\": \"Ligand binding assays, soluble fusion protein treatment in vitro/in vivo, gene-deficient mouse autoimmune models\",\n      \"pmids\": [\"21416464\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether TIGIT outcompetes CD226 through affinity or stoichiometry not resolved\", \"Additional ligands not yet explored\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Demonstrating that TIGIT disrupts CD226 homodimerization in cis and that co-blockade of TIGIT with PD-L1 synergistically restores CD8+ T cell function revealed a dual inhibitory mechanism (ligand competition plus direct receptor-receptor interaction) and established the rationale for combination checkpoint immunotherapy.\",\n      \"evidence\": \"Antibody blockade in murine tumor and chronic viral infection models, CD226 dimerization assays\",\n      \"pmids\": [\"25465800\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of cis TIGIT-CD226 interaction unresolved\", \"Whether cis disruption versus ligand competition dominates in different contexts unknown\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"The discovery that Fusobacterium nucleatum Fap2 protein directly binds TIGIT to inhibit NK cell and T cell cytotoxicity revealed a microbial co-option of TIGIT for immune evasion in colorectal cancer.\",\n      \"evidence\": \"F. nucleatum mutant library screen, direct protein interaction assays, NK cell cytotoxicity assays\",\n      \"pmids\": [\"25680274\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Binding interface of Fap2 on TIGIT not structurally characterized\", \"Whether other bacterial species exploit TIGIT unknown\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Showing that TIGIT-CD155 interaction drives MHC-I-independent NK cell education and that tumor-derived CD155 suppresses CD8+ T cell glucose metabolism linked TIGIT's inhibitory role to both NK cell maturation and metabolic reprogramming of effector cells.\",\n      \"evidence\": \"TIGIT-KO and CD155-KO mouse models with NK functional assays; T cell-tumor coculture with CD155 silencing/overexpression and glucose supplementation rescue\",\n      \"pmids\": [\"28438433\", \"28883004\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Which metabolic sensors downstream of TIGIT mediate glucose deprivation effects not identified\", \"NK education mechanism molecularly undefined\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Demonstrating that TIGIT blockade prevents NK cell exhaustion in tumors and that high TIGIT/low CD226 on tumor-infiltrating Tregs enhances suppressive function established TIGIT as a functional checkpoint on multiple immune cell lineages within the tumor microenvironment.\",\n      \"evidence\": \"TIGIT antibody blockade in multiple mouse tumor models with NK depletion epistasis; flow cytometry and Treg suppression assays on melanoma patient samples\",\n      \"pmids\": [\"29915296\", \"30046006\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether TIGIT signaling in Tregs and NK cells uses identical downstream pathways unclear\", \"Treg data correlative without genetic Treg-specific deletion\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Identifying glucocorticoid receptor signaling as a direct transcriptional regulator of TIGIT expression on T cells linked neuroendocrine stress pathways to immune checkpoint regulation.\",\n      \"evidence\": \"GR antagonist RU486 treatment, Lck-Cre conditional GR knockout, corticosterone administration in vitro/in vivo\",\n      \"pmids\": [\"31108170\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether GR binds the TIGIT promoter directly or through intermediary factors not resolved\", \"Relevance to tumor-associated stress not tested\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Revealing that membrane-bound CD155 triggers CD226 internalization/degradation on NK cells, that anti-TIGIT therapeutic efficacy requires FcγR engagement on myeloid cells, and that B cell-specific TIGIT deletion causes spontaneous CNS inflammation collectively expanded TIGIT biology beyond direct receptor blockade to include receptor dynamics, Fc-dependent myeloid modulation, and B cell tolerance.\",\n      \"evidence\": \"CD226 internalization assays and TIGIT-KO NK transfer (PMID:32591463); Fc-functional vs. Fc-null anti-TIGIT antibodies in mouse tumor models (PMID:33117369); B cell-specific conditional TIGIT KO mice developing CNS pathology (PMID:32668241); TIGIT+ B cell co-culture with T cells and DCs (PMID:33750787)\",\n      \"pmids\": [\"32591463\", \"33117369\", \"32668241\", \"33750787\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular mechanism of Fc-dependent 'reverse activating signals' through FcγR incompletely characterized\", \"Whether B cell TIGIT tolerance function is CD155-dependent not definitively shown\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Defining the SHIP-1-dependent NF-κB/ERK inhibitory signaling cascade downstream of TIGIT phosphorylation, identifying TCF4 as a transcriptional regulator of TIGIT on B cells, solving the TIGIT–anti-TIGIT antibody crystal structure, and confirming FcγR-dependent anti-TIGIT/lenalidomide synergy in myeloma provided intracellular signaling, transcriptional, structural, and therapeutic mechanistic resolution.\",\n      \"evidence\": \"Western blot for NF-κB/ERK after TIGIT/CD155 blockade with SHIP-1 recruitment (PMID:35729552); TCF4 dysregulation analysis in MS B cells (PMID:36250467); X-ray crystallography of MG1131-TIGIT complex (PMID:35090381); Fc-functional vs. Fc-null anti-TIGIT with CD8 depletion in myeloma model (PMID:36512425)\",\n      \"pmids\": [\"35729552\", \"36250467\", \"35090381\", \"36512425\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether SHIP-1 is the sole proximal effector or acts with other phosphatases unknown\", \"TCF4 regulation based on patient-derived correlative data, direct TCF4 binding to TIGIT locus not shown\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Super-resolution imaging revealed that TIGIT reorganizes into dense nanoclusters at the immune synapse that coalesce with TCR clusters in an ITT-like motif-dependent manner, establishing the spatial mechanism of TIGIT-mediated inhibition; simultaneously, nectin-4 was identified as an additional TIGIT ligand, and TIGIT was shown to mediate ILC2 activation-induced cell death via CD155 on macrophages.\",\n      \"evidence\": \"Super-resolution microscopy with ITT-motif mutagenesis (PMID:37596248); SPR and structure-guided mutagenesis for nectin-4 binding (PMID:37542773); TIGIT lineage tracer mice, KO, and anti-TIGIT blockade with ILC2 apoptosis assays (PMID:37036426)\",\n      \"pmids\": [\"37596248\", \"37542773\", \"37036426\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether nanocluster formation occurs with all TIGIT ligands or is CD155-specific not tested\", \"Nectin-4 functional relevance in vivo not established\", \"Downstream apoptotic pathway in ILC2s not molecularly defined\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Defining PI3K/AKT/mTOR as the metabolic signaling axis suppressed by CD155/TIGIT in CD8+ T cells, and showing that platelet-contact-induced CD155 on circulating tumor cells specifically engages TIGIT (not CD96 or DNAM-1) to evade NK surveillance, refined the metabolic and metastatic evasion mechanisms of the TIGIT axis.\",\n      \"evidence\": \"Western blotting for PI3K/AKT/mTOR with glucose/lactate assays in TNBC model (PMID:38216949); receptor competition assays and FAK/JNK/c-Jun pathway analysis in hepatocellular CTC-NK model (PMID:38779918)\",\n      \"pmids\": [\"38216949\", \"38779918\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether PI3K/AKT/mTOR suppression is downstream of SHIP-1 or represents a parallel pathway not resolved\", \"In vivo validation of CTC-specific CD155/TIGIT metastasis axis limited to one tumor type\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Outstanding questions include: (1) how TIGIT's multiple intracellular signaling modules (ITT-like motif, SHIP-1, PI3K/AKT/mTOR suppression) are hierarchically integrated; (2) whether TIGIT nanocluster formation is ligand-specific and how it relates to cis CD226 disruption at the structural level; (3) the physiological relevance of nectin-4 as a TIGIT ligand in vivo; and (4) which Fc-effector mechanism (ADCC, reverse signaling, or both) drives therapeutic anti-TIGIT antibody efficacy in human tumors.\",\n      \"evidence\": \"Open question derived from cumulative literature gaps\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Integrated signaling model connecting SHIP-1, PI3K, and nanocluster formation missing\", \"No resolved structure of TIGIT-CD226 cis complex\", \"Nectin-4 in vivo studies lacking\", \"Human FcγR mechanism for anti-TIGIT not mechanistically dissected\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 2, 15, 17]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [1, 5, 15, 17]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [2, 10, 17, 20]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 2, 7, 8, 12, 15, 17]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [6, 15, 23]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [18]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"CD155\",\n      \"CD112\",\n      \"CD226\",\n      \"SHIP-1\",\n      \"Fap2\",\n      \"nectin-4\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}